c

Nice | Rivaroxaban for DVT treatment

21st August 2012 by Louise Hudman

This guideline advises that Rivaroxaban can now be considered for use in the treatment of proximal DVT. It is as effective as warfarin, but is more expensive. I suspect we will need to await local approval before use. It doesn’t require monitoring.

It is contraindicated with GFR < 30 and ‘very high blood pressure’ among other things. Use is normally for 3m, though may be needed for longer if there are ongoing risk factors for VTE. It hasn’t really been studied beyond 12m, so use beyond that is of uncertain effectiveness (though is allowed).

Interestingly, there is a higher risk of non-major bleeding with rivaroxaban than on warfarin, though a similar rate of major bleeding.

Read more

No credit card details needed – it takes two minutes.

Join free trial

Login

Already a member? Login to view this content.

Login

"I started working as a locum GP in January this year and NASGP have been invaluable in helping to co-ordinate my bookings and organise all the administrative aspects of sessional work which can be complex and time consuming. Their client support is outstanding and they have always resolved any queries promptly and personally. They care about the service they provide and I would not hesitate to recommend them to any sessional GPs who want to minimise time spent on administration and focus on providing patients with high quality care."

Dr Paul Riley, GP

Dr Paul Riley, GP

See the full list of features within our NASGP membership plans

Membership